Perspective

CYP1A Induction and Human Risk Assessment: An Evolving Tale of in vitro and in vivo Studies

Qiang Ma and Anthony Y. H. Lu

Receptor Biology Laboratory, Toxicology and Molecular Biology Branch, Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Morgantown, West Virginia (Q.M.); and Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, New Jersey (A.Y.H.L.)

Received March 16, 2007; accepted April 11, 2007

ABSTRACT:

CYP1A1 and 1A2 play critical roles in the metabolic activation of carcinogenic polycyclic aromatic hydrocarbons (PAHs) and heterocyclic aromatic amines/amides (HAAs), respectively, to electrophilic reactive intermediates, leading to toxicity and cancer. CYP1A1s are highly inducible by PAHs and halogenated aromatic hydrocarbons via aryl hydrocarbon receptor-mediated gene transcription. The impact of CYP1A1 induction on the carcinogenic and toxic potentials of environmental, occupational, dietary, and therapeutic chemicals has been a central focus of human risk evaluation and has broadened the fields of cancer research, toxicology, pharmacology, and risk assessment over the past half-century. From the early discovery of CYP1A induction and its role in protection against chemical carcinogenesis in intact animals, to the establishment of CYP1A enzymes as the principal cytochromes P450 for bioactivation of PAHs and HAAs in vitro assays, to the recent realization of an essential protective role of CYP1A in benzo[a]pyrene-induced lethality and carcinogenesis with CYP1A knockout mice, the understanding of the interrelation between CYP1A induction and chemical safety has followed a full circle. This unique path of CYP1A research underscores the importance of whole animal and human studies in chemical safety evaluation.

Humans are constantly exposed to harmful foreign chemicals and materials from dietary, therapeutic, environmental, and occupational sources. As such, defense mechanisms have evolved to protect against toxic insults. The cytochrome P450 family of enzymes plays critical roles in the biotransformation of drugs, carcinogens, steroid hormones, and environmental toxicants (Lu, 1998; Conney, 2003; Guengerich, 2004; Coon, 2005). Cytochrome P450 1A1 and 1A2 catalyze the oxygenation of polycyclic aromatic hydrocarbons (PAHs) and heterocyclic aromatic amines/amides (HAAs), the demethylation of aminoazo dyes, and the dealkylation of phenacetin and caffeine and other therapeutic agents (Conney, 1982; Kim and Guengerich, 2005). Oxygenation of the chemicals by 1A1 and 1A2 serves as an initial step in the conversion of the substrates to more polar metabolites, resulting in increased excretion and thereby maintaining the chemical homeostasis in the body. However, oxygenation of carcinogenic PAH and HAA (procarcinogen) gives rise to arene oxide, diol epoxide, and other electrophilic reactive species (ultimate carcinogen) that form DNA and protein adducts, leading to tumor formation and toxicity (Gelboin, 1980; Miller and Miller, 1981; Conney, 1982; Jerina, 1983). Humans encounter PHAs and HAAs from a wide range of sources such as tobacco smoke, automobile exhaust, smoked and cooked food, and industrial processes. Such exposures have been causatively linked to an increased incidence of cancers in certain populations such as smokers (Proctor, 2001). Thus, the metabolic activation of PAHs and HAAs by P450 1A enzymes is a critical step in the formation of cancer in human populations exposed to PAHs and HAAs.

A remarkable feature of P450 1A1/2 action is that the enzymes are highly inducible at both mRNA and enzyme levels by a range of chemicals (Whitlock, 1999; Ma, 2001). Inducers in many cases are substrates of the enzymes such as benzo[a]pyrene (B[a]p) and 3-methylcholanthrene (3-MC). CYP1A1 is expressed at low levels in extrahepatic tissues. CYP1A2 is constitutively expressed in the liver and extrahepatic tissues in humans but is highly inducible in the liver and extrahepatic tissues. CYP1A2 is constitutively expressed in the liver and is inducible. Induction of CYP1A1 by PAHs is mediated through the aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor. Binding of PAH to AhR elicits sequential signaling events leading to the activation of AhR and transcription of CYP1A genes through the dioxin response element located in the enhancers of the AHR-responsive genes.
genes. In this framework, PAH, AhR, dioxin response element, and CYP1A1/2 form a receptor-mediated transcriptional loop that directly senses the concentrations of PAH in cells and increases the activities of the enzymes through transcription. Induction subsides as PAH is metabolized to ensure that induction is initiated and maintained only as needed. Therefore, induction is not only necessary for clearance of chemicals in the body but also tightly regulated according to the cellular concentrations of xenoc hemicals.

The biological impact of CYP1A induction can be 2-fold. Induction of CYP1A in general serves as a means of maintaining the homeostasis of the chemical environment in cells by increasing the metabolic clearance of substrates. Since CYP1A1/2 catalyzes the metabolic activation of PAHs and HAAs to ultimate carcinogens, it is expected that induction of the enzymes is detrimental in humans who are exposed to high levels of PAHs and HAAs such as by cigarette smoking. Moreover, induction of the enzymes in humans exhibits large variations (Ma and Lu, 2003); high inducibility may impose additional risk for lung cancer to individuals who are smokers. Furthermore, CYP1A1/2 can metabolize a range of substrates; induction of the enzymes by one substrate may increase the metabolism of other chemicals (for instance, clinical drugs), resulting in unexpected drug-drug interactions (DDIs).

Because of the critical role of CYP1A in chemical carcinogenesis and toxicity, the implication of CYP1A induction in human risk evaluation has been and remains a central focus of interest in cancer research, drug development, toxicology, food safety, and environmental/occupational health since the discovery of CYP1A induction. In this review, we analyzed the evidence accumulated over the past five decades that implicates CYP1A induction in the biological effects of carcinogens, drugs, and environmental chemicals both as beneficial and detrimental responses. It is our hope that such analysis would provide new insights into the human safety analysis of P450 induction and be instrumental to the application of in vitro and in vivo reactions in human risk assessment.

The Discovery of CYP1A Induction: Initial Observations of the Impact of CYP1A Induction on Cancer and Toxicity

The discovery of CYP1A induction originates from the observation that PAH induces its own metabolism (Conney, 2003). These early studies have also provided the initial in vivo evidence demonstrating large impacts of CYP1A induction on the toxicity and carcinogenesis of certain chemicals in animals. In 1952, Richardson and associates (Richardson et al., 1952) reported that coadministration of a strong hepatocarcinogen, 3′-methyl-4-dimethylaminoazobenzene (3′-Me-DAB) with a low dose of 3-MC in rats delayed or entirely inhibited liver tumor development that was observed in rats treated with 3′-Me-DAB alone. Inhibition was also seen for 3′-Me-DAB-induced liver cirrhosis. The findings demonstrated protection by 3-MC against the carcinogenicity and toxicity of 3′-Me-DAB. Miller et al. (1958) showed that the inhibition of carcinogenesis by 3-MC and other PAHs is not just specific for 3′-Me-DAB, but also for tumorigenicity by aminoazo dyes, 2-acetylaminofluorene, and 2-acetylaminofluorene derivatives.

A critical issue arises from these in vivo inhibition studies: what accounts for the protective effect of PAHs? To address the question, Conney et al. (1956) examined the effects of treating rats with 3-MC and other PAHs on the hepatic N-demethylation and azo link reduction of aminoazo dyes, which are metabolic pathways resulting in noncarcinogenic products. The findings revealed that PAHs that inhibited aminoazo dye-induced liver cancer were potent inducers of aminoazo dye N-demethylase, whereas those PAHs that did not affect aminoazo dye-induced carcinogenesis had little or no effect on aminoazo metabolism. This and subsequent other studies provided early evidence of CYP1A induction and a mechanistic explanation for the protective effect of PAHs on aminoazo carcinogenesis (Conney, 2003). The studies opened the gateway of research on P450 induction that had profound influence on the development of drug metabolism, cancer research, pharmacology, and toxicology over the following half-century.

Mouse Genetics in CYP1A Induction

Mouse genetics contributed greatly to the understanding of the mechanism of CYP1A induction. Induction was measured as an increase in the aryl hydrocarbon hydroxylase (AHH) activity (i.e., 3-hydroxylation of B[a]p). Some inbred mouse strains such as C57BL/6 (B6) are sensitive to induction by 3-MC, whereas other strains such as DBA/2 (D2) are resistant to the induction (Nebert and Gelboin, 1969; Kodama and Bock, 1970). The sensitive phenotype was segregated as a single autosomal dominant trait (Gielen et al., 1972; Thomas et al., 1972). The polymorphism of the genetic trait defines a genetic locus, which was designated as the Ah locus (aromatic hydrocarbon responsiveness). AhR represents the “Ah responsive” or B6 allele and AhR the “Ah nonresponsive” or D2 allele. Thus, genotypes of b/b and d/d give high induction of CYP1A, whereas that of d/d is nonresponsive. Later, the b allele was further separated into b-1 (C57BL/6), b-2 (C3H), and b-3 (Mus spretus) alleles (Polland et al., 1994).

Among the inducers of CYP1A, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD, dioxin) was found to be the most potent for the induction of the enzymes. TCDD and 3-MC produce parallel log dose-response curves for the induction of AHH activity. However, TCDD is about 30,000 times as potent as 3-MC (Poland and Glover, 1974). In addition, induction by TCDD is persistent compared with that by PAH (>35 versus 8 days) because of its long half-life (t½ = 17 days in rats); the symmetrical localization of chlorine atoms on the ring structure of TCDD gives rise to its resistance to metabolic breakdown and prolonged t½. Induction by TCDD and its congeners is stereospecific in structure. Whereas TCDD potently induces AHH with an EDD₅₀ of 1 nmol/kg in responsive strains, the induction is also observed in all nonresponsive strains with an EDD₅₀ of about 10 nmol/kg (Poland and Glover, 1975). The heterozygous genotype (b/d) exhibits intermediate sensitivity to TCDD, which is distinguishable from b/b and d/d strains (Niwa et al., 1975). These observations suggest a diminished affinity for inducers in D2 mice as a cause of nonresponsive phenotype in CYP1A induction by PAHs (Poland and Glover, 1975).

The comparative studies on the potency and stereospecificity among the inducers and between the Ah-responsive and -nonresponsive strains for CYP1A induction, and later the demonstration of reversible, saturable, and high-affinity binding of radiolabeled TCDD to a soluble cytoplasmic protein of hepatocytes, provided pharmacological evidence that the Ah locus product functions as an “induction receptor,” designated as the aryl hydrocarbon receptor (AhR) (Poland and Glover, 1974, 1975; Poland et al., 1976). In this regard, AhR binds a CYP1A inducer and mediates the induction of the genes. In addition to CYP1A induction, “other biological effects” of CYP1A inducers, typified by TCDD, also segregate with the high-affinity AhR genotype, implicating AhR in a broader range of biological effects of the inducers than CYP1A induction. These effects include a wasting syndrome, thymic involution, altered proliferation and differentiation of epithelial cells, endocrine disorders, and tumor promotion, which were collectively known as the “adverse response” of halogenated aromatic hydrocarbons to reflect the fact that they were observed in animals treated with a single dose of TCDD and related halogenated dibenzo-p-dioxins, dibenzofurans, and biphenyls.
The availability of mouse strains with high- and low-affinity AhRs provided a unique approach to the analysis of CYP1A induction and PAH carcinogenicity and toxicity (Nebert, 1989) (Table 1). In addition to differences in the sensitivity of the strains for both induction and toxicity by PAH, apparent disparities were observed in the patterns of PAH-induced tumors and toxicity between Ah-responsive (b/b or d/d) and nonresponsive (d/d) mice: b/b and d/d mice are more prone than d/d mice to PAH-induced cancers and toxicity in target tissues with which an administered PAH is in direct contact, such as the liver, skin, and lungs, whereas d/d mice are at greater risks than b/b and d/d mice of developing tumor and toxicity in organs distant from the site of administration, such as the bone marrow. Strikingly, B[a]p given in diet at a dose of 120 mg/kg/day caused all d/d mice to die within 3 to 4 weeks, whereas b/b or d/d mice survived the treatment for 6 months (Robinson et al., 1975). At low doses (6 or 12 mg/kg/day) of B[a]p, the d/d mice survived but developed more leukemia than did b/b or control mice (Nebert and Jensen, 1979). It was hypothesized that CYP1A induction (and, consequently, the metabolic activation and clearance of PAH) is high in the liver (and other sites of entry) in B6 mice, resulting in a significant first-pass effect of B[a]p metabolism, leading to tumor and toxicity at proximate sites. On the contrary, induction is weak in D2 mice, thus allowing more PAH to reach remote organs, giving rise to increased tumor formation and toxicity at distant sites. This observation underscores the importance of both the dosage and route of administration in the evaluation of the impact of CYP1A induction on chemical toxicity. The findings suggest a protective role of CYP1A induction in the gut and/or liver against the bone marrow toxicity of high level oral B[a]p. However, the studies do not distinguish whether the phenotypic difference between the responsive and nonresponsive mice is due to the low activities of CYP1A, the Ah locus product, or both in D2 mice.

Thus, alternatively, activation of AhR or induction of target genes other than CYP1A may contribute to the observed differences in B[a]p toxicity between the Ahb and Ahd mice.

**Effect of CYP1A Induction on Toxicity and Cancer: Early in Vitro and Human Studies**

Since the early 1970s, a number of innovative in vitro approaches were developed and popularized rapid analyses of the carcinogenic and toxic effects of large numbers of chemicals under simple in vitro conditions. The application of these in vitro assays has led to several critical observations in the understanding of the interrelation between the biological effect of PAH and its metabolism by CYP1A (Table 1). The “Salmonella/lever enzymes” (or “Ames”) test was employed to analyze the metabolic activation of 3-MC to mutagens with hepatic S-9 fractions from b/b, b/d, or d/d mice (Felton and Nebert, 1975). The findings revealed a correlation between induction of CYP1A1 enzyme activity and increased mutagenic activity of 3-MC. Many other PAHs were found to require bioactivation by CYP1A1 for their mutagenic effects in the Ames test, as well, consistent with a linear mechanistic linkage among CYP1A induction, metabolic activation, mutagenesis, and tumorigenicity of PAHs.

The V79 Chinese hamster cell line contains the NADPH-cytochrome P450 reductase but lacks P450-dependent activities. Genetic engineering of the cells with P450s reconstitutes the metabolic capability, thus permitting genotoxicity testing, in which mutagenic metabolites are both generated and detected in one cell type (Eillard et al., 1991). V79 cells have also been widely used in cocultivation experiments with liver enzymes. By comparing the genotoxicity of PAH in V79 cells expressing different P450s, 3-MC was found to depend on CYP1A1 for its mutagenicity, whereas 2-aminoanthracene requires CYP1A2 and an acetyltransferase activity to elicit high mutagenic response. Moreover, tobacco particulates were found to induce a greater formation of micronuclei in cells expressing CYP1A1 compared with V79 cells lacking the enzyme, implicating PAHs, in addition to direct-acting components, in the genotoxicity of tobacco particulate matter (Eillard et al., 1991).

The 1970s were also marked by the elucidation of the chemical structures of the metabolites and the pathways of bioactivation of PAHs. More importantly, through the use of a combination of in vitro (Ames test, V79 culture, and rat microsome or P450 fractions) and in vivo assays, the trans-7,8-Diol 9,10-epoxide metabolite of B[a]p was found to be the major metabolic product of the rat CYP1A1 enzyme.
and the principal ultimate mutagen and carcinogen of B[a]p (Conney, 1982; Jerina, 1983; Miller and Ramos, 2001). From these studies, the concepts of pro-, proximate, and ultimate carcinogens were developed. The studies also established the induction of the CYP1A1 enzyme activity as a primary event in the formation of the trans-7,8-diol 9,10-epoxide of B[a]p.

The consequence(s) of B[a]p bioactivation by CYP1A in cultured cells was best illustrated in the selection of B[a]p-resistant variants in hepali c7 cells, a mouse hepatoma cell line that preserves many of the hepatocyte properties and is highly responsive to induction of CYP1A by PAH inducers (Whitlock, 1990; Hankinson, 1995). Upon exposure to B[a]p, most hepali c7 cells died, presumably because of the toxicity of trans-7,8-diol 9,10-epoxide formed from B[a]p, corresponding to increased DNA and protein adduct formation. A few resistant variants, however, grew in the presence of B[a]p. Complementation experiments separated the variants into at least three complementation groups that were later defined as the genes encoding CYP1A1, AhR, and aryl hydrocarbon receptor nuclear translocator (Arnt), respectively. Thus, a transcription circuit is created: B[a]p activates AhR and Arnt to mediate the induction of CYP1A1, which metabolize B[a]p to toxic intermediates, leading to cell death. The findings established that induction of CYP1A1 is a primary determinant of B[a]p toxicity in cultured cells.

Analyses of the induction of AHH activity in human tissues or cultured human cells provided the initial observations of CYP1A induction in humans. Early studies by Conney and associates first revealed that AHH activity was detected in placentas obtained after birth from smoking mothers, but not from nonsmokers, consistent with an induction of CYP1A by PAHs present in tobacco smoke (Welch et al., 1969). However, AHH activities in placentas from mothers who smoke the same amount of cigarettes exhibit variations as large as 84-fold. In cultured neonatal human foreskin cells, basal AHH activities were detected with a 3-fold variability. The activity was inducible by benz[a]anthracene with a large variation (from 180 to 530%) among the testing individuals (Alvares et al., 1973).

By using a mitogen-activated, PAH-treated human lymphocyte culture system, Kellermann et al. (1973a) observed that the normal white population in the United States can be divided into three distinct groups with low, intermediate, and high degrees of inducibility of AHH activity. Phenotype frequencies were 53%, 37%, and 10%, respectively. Furthermore, by using the same assay, the same group found a close association between the susceptibility to bronchogenic carcinoma and high inducibility of AHH activity in 50 cancer patients (Kellermann et al., 1973b).

These studies not only revealed large variations in the induction of CYP1A in human populations, but also suggest a causative role of CYP1A induction in the occurrence of cancer in certain human populations. Subsequent reports provided evidence supporting a correlation between high CYP1A inducibility and cancer of the lung, larynx, and oral cavity that are in direct contact with cigarette smoke. However, it is noteworthy to point out that no association between lung cancer and CYP1A inducibility has been reported in a number of studies (Ma and Lu, 2003).

Together, from these early in vitro, mechanistic, and human studies, it appears to be logical to conclude that induction of CYP1A would impose detrimental effects upon individuals by way of metabolic activation of PAHs and other chemicals to ultimate carcinogens or reactive toxic intermediates.

The Ah Receptor

A major obstacle to the study of the Ah receptor in the 1970s and 1980s was the difficulty in purifying the protein to homogeneity. By using 2-azido-3-[125]iodo-7,8-dibromodibenzo-p-dioxin, a photoaffinity ligand of AhR, Bradfield et al. (1991) were able to covalently label the Ah receptor from the liver of C57BL/6J mice and purify the protein to apparent homogeneity under denaturing conditions. The purification procedure involved two ion exchange chromatography steps, which gave ~100-fold enrichment and 40 to 50% recovery, followed by three rounds of C4 reverse phase high-performance liquid chromatography, to eventually reach a >150,000-fold purification with an overall yield of 3 to 5%. The putative amino-terminal sequence of the AhR peptide was determined from this preparation by peptide sequencing. A synthetic peptide based on the N-terminal amino acid sequence was used to raise polyclonal antibodies. The antibodies recognized both denatured and nonadenatured photoaffinity-labeled Ah receptor from C57BL/6J mouse liver as a 95-kDa protein (Poland et al., 1991). The antibodies also recognized AhR from chicken, rodent, monkey, and human, indicating conservation of the N-terminal epitope.

Cloning of the AhR cDNA (b-1 allele) using degenerate oligo probes derived from the putative N-terminal peptide sequence revealed that AhR contains 805 amino acid residues with a calculated molecular mass of 89,426 Da (Burbach et al., 1992). Importantly, the N-terminal region of AhR contains a stretch of basic residues followed by a helix-loop-helix turn motif; the structure is termed “bHLH” and is commonly seen among members of the bHLH family of transcription factors. The bHLH motif functions as the DNA-binding and protein dimerization domain of the transcription factors. In addition, the AhR protein contains two imperfect inverted 51-amino acid repeats adjacent to bHLH that were also found in Per, which is a circadian transcription factor. Arnt, which is the dimeric partner of AhR for CYP1A transcription, and Sim, which is the Drosophila “single-minded” protein. The motif was named the “PAS” motif (Hoffman et al., 1991). The PAS motif of AhR was found to involve ligand binding, binding with the hsp90 protein in the cytoplasm, and dimerization of AhR with Arnt in the nucleus. The carboxyl half of AhR contains three separable transcription activation domains that are acidic, serine/threonine-rich, and glutamine-rich, respectively (Ma et al., 1995). Thus, AhR was formally classified as a ligand-activated transcription factor of the bHLH-PAS family.

Human AhR is about 10-fold less sensitive to the induction of AHH activity by TCDD than is B6 AhR in parallel with a 10-fold lower binding affinity for TCDD, resembling the Ah-nonresponsive phenotype (Harper et al., 1988). Cloning of human AhR cDNA revealed that it encodes a protein of 848 amino acid residues (Ema et al., 1994).

Structurally, the human AhR is more similar to the D2 AhR than to the B6 AhR, with two critical determinants reducing ligand-binding affinity observed in D2 AhR: a T to G mutation at the position equivalent to the termination codon (TGA) of the B6 AhR, causing an elongation of the carboxyl terminus, and a Val181 equivalent to the Val75 of D2 AhR replacing Ala75 of B6 AhR. Scatchard plot analysis of expressed human AhR gave a Kd value of 1.58 nM for TCDD in agreement with that of D2 AhR (1.66 nM), ~6-fold higher than that of B6 AhR (0.27 nM); the Kd values of the mouse AhRs are qualitatively similar to those reported earlier (16 nM for D2 and 1.8 nM for B6) (Okey et al., 1989).

The CYP1A Knockout Mouse Models

The construction of targeted knockout mouse models of the cyp1a1, cyp1a2, cyp1b1, and double knockout of the genes made it possible to directly evaluate the role of CYP1A in chemical toxicity and carcinogenesis in intact animals. Distinctly contradictory to the observations from in vitro studies that CYP1A enhances the toxicity of PAHs,
the intact animal experiments after oral dosing revealed an essential protective role of CYP1A induction in PAH toxicity (Nebert et al., 2004) (Table 1). An oral dose of B[a]p at 125 mg/kg/day caused death of all cyp1a1−/− mice within 30 days, whereas no mortality or apparent signs of toxicity were observed in cyp1a2+/− mice receiving the same treatment (Uno et al., 2004). Pathological lesions observed included striking decreases in the sizes of spleen and thymus, leukocytopenia, and extreme hypocellularity of the bone marrow in cyp1a1−/− mice that may have caused the lethality. Increased toxicity of B[a]p in cyp1a1−/− mice correlated with a slower clearance rate (4 times slower), but a higher amount of B[a]p-DNA adduct formation, typically in the liver, spleen, and bone marrow, but not the small intestine, in cyp1a1−/−, but not cyp1a2+/− mice. Protection against B[a]p-induced mortality by CYP1A1 was not observed when B[a]p was administered at 125 mg/kg via i.p. injection.

A similar experiment was conducted comparing cyp1a1−/−, cyp1a2−/−, cyp1b1−/−, cyp1al−/−/cyp1b1−/−, cyp1a2−/−/cyp1b1−/−, and cyp1+/+ mice (oral B[a]p of 125 mg/kg/day for 18 days) (Uno et al., 2006). Marked wasting, immunosuppression, and bone marrow hypocellularity were observed only in cyp1a1−/− mice. Together, these studies provide a conclusive proof of a protective role of CYP1A1 induction in the intestine and/or liver against the immune and bone marrow toxicity of oral B[a]p. In addition, the studies revealed that the immune and bone marrow toxicity, but not the thymic atrophy and hepatocyte hypertrophy effects, of oral B[a]p required CYP1B1, and the magnitude of the immune damage can be independent of total plasma B[a]p concentration and clearance.

The cyp1a2−/− mice exhibited increased toxicity from drugs that are predominantly CYP1A2 substrates. Paradoxical results were observed concerning the role of CYP1A2 in the tumorigenicity of 4-aminobiphenyl (ABP) (Tsuneoka et al., 2003). CYP1A2 enhanced the metabolic activation, ABP-DNA adduct formation, and toxicity in vitro. However, cyp1a2−/− mice exhibited increased adducts in the liver and urinary bladder by topical ABP; ABP-induced hepatocellular carcinomas and preneoplastic foci as well as ABP-induced methemoglobinemia were increased in the mice. Similar paradoxical roles of CYP1A2 were observed in the DNA adduct formation and malignancies induced by 2-amino-3-methylimidazo[4,5]quinoline and 2-amino-1-methyl-6-phenyl-imidazo[4,5]pyridine (Snyderwine et al., 2002; Kimura et al., 2003). The results demonstrate alternative pathways of metabolic activation of ABP, 2-amino-3-methylimidazo[4,5]quinoline, and 2-amino-1-methyl-6-phenyl-imidazo[4,5]pyridine in the absence of CYP1A2 and protection against adduct formation of the chemicals by CYP1A2 in intact animals.

The more “stable” ligands of AhR, exemplified by TCDD, can cause a broad range of adverse responses in animals in an AhR-dependent manner in addition to CYP1A induction. The mechanism of the toxic effects of TCDD is not well understood. TCDD is a poor substrate of CYP1A1 and does not form reactive intermediates. The interrelation between CYP1A1 induction and TCDD toxicity remains a subject of debate. The teratogenic effect of TCDD (cleft palate formation and hydrencephrosis) was assessed in cyp1a1−/−, cyp1a2−/−, and cyp1b1−/− mice (Dragin et al., 2006). TCDD at 25 µg/kg by gavage on gestation day 10 was found to be lethal to fetuses carried by cyp1a2−/−, but not cyp1a1−/− or cyp1b1−/−, dams. Fetuses from cyp1a2−/− dams exhibited a 6-fold increase in sensitivity to cleft palate, hydrencephrosis, and lethality. The effect was dependent on the maternal cyp1a2−/− genotype and correlated with more TCDD reaching the embryos from cyp1a2−/− dams. High levels of TCDD were found in adipose tissue, mammary gland, and blood of the cyp1a2−/− mothers, compared with the high level of TCDD in the livers of the cyp1a2+/− mothers. The increased sensitivity to TCDD-induced birth defect was reverted by expressing human CYP1A1 and 1A2 in cyp1a2−/− mice. Since TCDD binds to CYP1A2 to an appreciable amount in the liver, the results support the notion that maternal mouse hepatic CYP1A2 and its induction protects the embryos from TCDD-induced toxicity and teratogenic effects by way of sequestering TCDD in the maternal liver.

The Omeprazole Story

Omeprazole (brand names: Piłosec, Rapinex) is a proton pump (H+·K+-ATPase) inhibitor used for its high efficiency as a blocker of gastric acid secretion in gastric parietal cells. Omeprazole is used clinically for the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, and the Zollinger-Ellison syndrome. A major pathway of metabolism of omeprazole is its conversion to 5-hydroxy-omeprazole by CYP2C19 (Andersson, 1996). Metabolism to 5-O-desmethyl-omeprazole by CYP2C19, and to 3-hydroxy-omeprazole and omeprazole sulfone by CYP3A, constitutes the minor metabolic pathways of the drug.

Although omeprazole is not a substrate of CYP1A, it induced CYP1A1/2 in primary human hepatocytes at mRNA, protein, and enzyme (phenacetin deethylase, acetanilide hydroxylase, benzpyrene hydroxylase, and ethoxyresorufin deethylase) levels (Diaz et al., 1990). Induction of the CYP1A2 protein was from 4- to 50-fold, comparable to induction by 3-MC or β-naphthoflavone in cultured human hepatocytes. Moreover, 2- to 10-fold induction of the CYP1A2 protein and CYP1A1-dependent activities was observed in vivo in liver biopsies from cancer patients before and after 4-day treatment with omeprazole at therapeutic doses. The study established omeprazole as the first clinical drug to be characterized as an inducer of CYP1A1 in the human liver (Diaz et al., 1990).

The 5-hydroxylation of omeprazole by human liver microsomal preparations and the in vivo clearance of omeprazole in humans exhibit a large interindividual variation that correlates with the polymorphic phenotypes of S-mephenytoin hydroxylase (catalyzed by CYP2C19) (Sohn et al., 1992; Chiba et al., 1993). Differences in the rate of 5-hydroxylation between poor metabolizers (PMs) and extensive metabolizers (EMs) results in different tissue levels of omeprazole available for CYP1A induction (Tang et al., 2005). At a therapeutic dose (40 mg), omeprazole failed to induce CYP1A2 as measured by a caffeine N-3-demethylation breath test in individuals with EM phenotype, but the induction was revealed at a higher dose (120 mg) in the same individuals. On the other hand, induction of CYP1A2 by omeprazole was observed in individuals with PM phenotype at the dose of 40 mg. Clearly, individual variations in the metabolic rate of omeprazole affect the intracellular concentration of the inducer contributing to variability of CYP1A induction (Rost et al., 1992, 1994).

In several clinical studies, induction of CYP1A2 by omeprazole was examined using CYP1A2 marker drugs (caffeine and phenacetin) in human volunteers who were not phenotyped for CYP2C19. Induction of caffeine and phenacetin metabolism by CYP1A2 was not observed (Andersson et al., 1991; Xiaodong et al., 1994; Rizzo et al., 1996). It is noteworthy that these studies were conducted in white populations, in which only a small portion of the population are PMs, whereas most individuals are EMs. Therefore, induction of CYP1A1 cannot be observed with 40 mg of omeprazole in these populations. Cancer patients in general have a decreased capacity of drug metabolism; therefore, many of them represent PM subjects. This notion may explain why marked induction of CYP1A by omeprazole was observed in the study of cancer patients by Diaz and associates discussed above (Diaz et al., 1990).
The finding of CYP1A induction by omeprazole in humans raised an issue of considerable clinical importance: induction of CYP1A by clinical drugs that are not known to be metabolized by CYP1A may induce unexpected DDIs; moreover, induction may exhibit high individual variability, making it more difficult to predict the impact of the induction on drug-drug interactions.

Since CYP1A2 is the major phenacetin deethylase in humans, induction of the enzyme by omeprazole would increase the metabolism of phenacetin to acetaminophen and, further, to the formation of N-acetyl-p-benzoquinoneimine, which is responsible for liver necrosis induced by the drugs. On the basis of this knowledge, it can be argued (Farrell and Murray, 1990) that acetaminophen liver toxicity could be increased in patients receiving both omeprazole and phenacetin or acetaminophen (two widely used analgesic drugs). Induction of CYP1A1 by omeprazole in patients who smoke may increase the chance of lung cancer due to increased metabolic activation of PAHs in the tobacco smoke by CYP1A1. In both scenarios, individuals with a PM phenotype of CYP2C19 are expected to have higher tissue concentrations of omeprazole, increased induction of CYP1A, and more formation of toxic and/or carcinogenic intermediates of phenacetin, acetaminophen, or PAHs from CYP1A1, leading to increased toxicity or tumorigenesis than individuals with an EM CYP2C19 phenotype. On the other hand, CYP1A2 catalyzes the 4-hydroxylation of aflatoxin B1, which represents an efficient pathway of detoxification of aflatoxin B1. Induction of CYP1A2 would increase metabolic detoxification of aflatoxin B1, resulting in decreased carcinogenicity of the compound (Koser et al., 1988). Thus, long-term treatment with omeprazole may provide a protective effect against aflatoxin B1-induced carcinogenesis in certain countries and regions where B1-induced liver cancer is a particular public health concern. However, clinical data supporting this notion are not available at present.

**CYP1A Induction and Drug Development**

The realization of the prominent role of inducible CYP1A1 in the metabolic activation of PAHs and that of CYP1A2 in the activation of HAA, phenacetin, and other drugs led to a widely held belief that induction of CYP1A is detrimental to humans and animals in general. This notion had a broad impact on chemical safety evaluation, in particular, in the area of carcinogenesis and environmental health. The role of CYP1A induction in drug development remains debatable and warrants certain clarification.

In two recent publications concerning CYP1A induction, it was stated that pharmaceutical companies employ a general policy for several decades: that, in routine drug development testing, if a candidate drug shows CYP1 inducibility, further testing is generally discontinued for fear of possible toxic or carcinogenic effects (Nebert et al., 2004; Uno et al., 2004). However, the two references cited to support this argument apparently did not address CYP1 induction as a general policy in drug screening (Valles et al., 1995; Gastel, 2001). There is a lack of supporting evidence for the statement in literature as well.

It is our understanding that, although potential induction of drug-drug interaction and bioactivation of toxic or carcinogenic compounds due to the induction of CYP1A1/1A2 have been of concern in safety in drug development, induction of CYP1A was rarely the deciding factor to determine whether a compound should be dropped for further testing because of its inducibility of CYP1A. In fact, omeprazole has been shown to be a CYP1A2 inducer both in cultured human hepatocytes and in the human liver (Diaz et al., 1990). Yet it was approved by regulatory agencies worldwide and has been used safely for more than 20 years by millions of people for clinical treatment of gastric ulcer and related disorders.

In the practice of drug development, it is recognized that induction of CYP1A2 can affect the drug level of coadministered drugs that are metabolized by CYP1A2. The issue is treated like the induction of other P450 enzymes such as CYP3A4. Drug-drug interactions can be evaluated by in vitro metabolism studies and by clinical DDI studies. The drug candidate is only dropped if it has very serious safety issues and clinically relevant DDI effects.

The clinical use of omeprazole provided an example of cancer risk evaluation of CYP1A inducers in drug development (Farrell and Murray, 1990). The CYP1A1 inducibility of omeprazole in humans and its interindividual variability associated with CYP2C19 phenotypes were well documented. Increased risk of malignancy in patients taking omeprazole is theoretically possible due to the critical role of CYP1A1 in the metabolic activation of PAHs and other carcinogens. On the basis of these considerations, it was suggested that patients for whom long-term administration of omeprazole is highly desirable should minimize exposure to cigarette smoke and dietary sources of PAHs such as char-broiled food, and continued long-term surveillance of such individuals for potential increase of malignancy was recommended (Farrell and Murray, 1990). However, the results from knockout mice and the safety record of omeprazole used by millions of individuals in over 20 years have not yet shown an etiological connection between omeprazole use and cancer incidence.

**Conclusion**

The discovery of induction of AH (CYP1A) in the 1950s led to the uncovering of a principal mechanism of regulation of drug metabolism. Moreover, studies of CYP1A induction had profound influence in broad areas of biomedical sciences including drug metabolism and drug development, cancer research, pharmacology, toxicology, and safety regulation of therapeutic agents and environmental and occupational chemicals. With regard to human safety evaluation, the research of CYP1A induction not only played a critical role in the understanding of the carcinogenicity and toxicity of PAH and other CYP1A substrates, but also served as a model system for analyzing the interrelations between induction of drug metabolism and chemical toxicity in general. Interestingly, from the early discovery of protection against chemical carcinogenesis via the induction of AH by PAHs in in vivo studies in the 1950s and 1960s, to the elucidation of the mechanism and biological implication of the metabolic activation of PAH procarcinogens to ultimate carcinogen (reactive intermediate metabolite) by CYP1A1/2 using in vitro approaches in the 1970s and 1980s, and to the demonstration of the protective role of CYP1A in B[a]P toxicity with the use of targeted gene knockout mice of the CYP1A genes in recent years, our understanding of CYP1A induction in chemical safety appears to have undertaken a full circle.

Two important lessons can be learned from the CYP1A induction experience for safety evaluation. First, in vitro studies permit mechanism-based analysis of a biological process at molecular levels, which can often be performed quickly and in large scale, allowing rapid analysis of large numbers of chemicals, whereas in vivo studies reflect intact animal response, but are often time-consuming, expensive, limited in the number of chemicals to be analyzed, and difficult in detailed mechanistic analysis. The uncovering of the critical role of the first-pass metabolism of PAH in intestine/liver by CYP1A1 in PAH toxicity and carcinogenesis clearly demonstrates the notion that precautions must be taken in the safety evaluation of P450 induction when extrapolating in vitro results to intact animals, since metabolism by P450 is often dependent upon organ, tissue, route and time of administration, age, gender, coadministered drugs or agents, and certain pathophysiological conditions. Second, from the early demonstration of large interindividual variation in AH induction in pl-
centa of smoking mothers to the recent observation of the association between CYPIA1 induction by omeprazole and the PM CYPC21 phenotype, human studies of CYPIA1 induction have uncovered multiple genetic and environmental factors influencing CYPIA1 inducibility and its impact on PAH carcinogenicity in humans. Thus, extrapolation of results from animal studies of P450 induction to humans is a complex process that requires, ultimately, the direct proof from human studies. Epidemiological studies of exposed populations may help address the relevance of animal studies.

References


**Address correspondence to:** Qiang Ma, Receptor Biology Laboratory, TMBB/HELD/NIOSH/CDC, Mailstop 3014, 1095 Willowdale Rd., Morgantown, WV 26505. E-mail: qam1@cdc.gov